Expression of RDX in cancer - Staining overview

The cancer tissue page shows antibody staining in 20 different cancers. The overall cancer tissue staining statistics shows the fraction of patient samples with high, medium, low or not detected (as described by the color-coding scale in the box to the right), using all the available antibodies to the protein targets encoded by this gene. The assay and annotation is described here.

The cancers can be ordered histologically or alphabetically.

For each cancer, the staining for each available antibody is reported as the fraction of samples with antibody staining level high, medium, low or not detected (as described by the color-coding scale in the box to the right). The length of the bar represents the number of patient samples analyzed (max=12 patients). By clicking on a cancer tissue, the detailed staining data for that cancer is available, including annotated images.

At the bottom of this page, a summary for the cancer staining for each antibody is given, together with the literature conformity for the staining pattern revealed by that specific antibody.

Antibody HPA000263

Antibody HPA000763

Antibody CAB037312

Tissue

Antibody staining

Summary

Liver, testis and urothelial cancers showed moderate cytoplasmic positivity. Remaining cancers were in general weakly stained or negative.

Gliomas, testis, urothelial, endometrial and ovarian cancers showed moderate to strong cytoplasmic positivity. Remaining tumor cells were generally negative.

Several gliomas, melanomas, urothelial, prostate, renal, endometrial and liver cancers along with a few pancreatic cancers displayed weak to moderate cytoplasmic positivity. Most other cancer cells were negative.

Literature conformity

Partly consistent with extensive gene/protein characterization data

Level of antibody staining/expression

High
Medium
Low
Not detected

The Human Protein Atlas project is funded by the Knut & Alice Wallenberg foundation.